logo-loader

Listings return Amphion Innovations to profit

Published: 08:32 23 Jun 2016 BST

picture of drugs
Motif Bio has rebooted Amphion's financial positon

Intellectual property specialist Amphion Innovations PLC (LON:AMP) swung strongly into the black as two of its portfolio companies, Motif Bio and Kromek, listed in London.

Net asset value shot up to 3.8p per share at end December from 0.7p a year earlier as the value of Amphion’s stake in antibiotic developer Motif more than doubled to US$27mln.

Profits for the year were US$5.94mln (US$12.6mln loss). Amphion was also able to raise its money (£2.1mln) on the equity market for the first time in seven years. Operating losses were US$4.16mln (US$3mln).

Datatern, another of its portfolio of investments, has made progress in its patent infringement case, Amphion added. Datatern is the plaintiff, with a trial scheduled to start in the third quarter of 2016.

Another tech patent infringement case, for portfolio company Axcess, has gone to the Texas Supreme Court.

Richard Morgan, chief executive, said the future of the company now rests around Motif Bio, Kromek and another portfolio company m2m.

“We are very actively supporting the development of both Motif and m2m and view the future of all three companies with optimism. 

“In addition, we continue to support DataTern's IP licensing programme and the recent successes in court reinforce our belief that we should see a good outcome from this programme in the next year or two. “

Amphion Innovations president on significant partner developments and strategy

Bob Bertoldi, president of Amphion Innovations PLC (LON:AMP) caught up with Proactive London’s Andrew Scott to discuss some of the big 2018 developments at the partner companies including Polarean Imaging (LON:POLX) and Motif Bio PLC (LON:MTFB) Polarean’s recently raised US$4mln through a...

on 14/12/18